Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025

Advancing Nasal Protection: Healthcare Innovations Beyond COVID-19

The Evolution of Nasal Protection Solutions The global scientific community continues to advance research on COVID-19 and its long-term effects, commonly referred to as “long COVID.” While the pathogenicity of COVID-19 has weakened due to viral mutations, the importance of infection prevention remains paramount. Repeated infections elevate the risk of long COVID, underscoring the need for sustained vigilance.

Beyond COVID-19, seasonal influenza remains a recurring public health challenge, leading to unpredictable pandemics and posing heightened risks for pregnant women, infants, the elderly, and individuals with chronic illnesses. These vulnerable populations are particularly susceptible to respiratory infections, making preventive measures a continued priority.

Given that nasal passages process thousands of litres of air daily, they act as the first line of defence against airborne pathogens. As a result, their high susceptibility to infections from influenza viruses, coronaviruses, rhinoviruses, and airborne allergens makes effective protective measures essential.

While face masks remain the gold standard for respiratory protection, discomfort and compliance issues have led to growing interest in nasal spray-based protection. Often referred to as “liquid masks,” these sprays do not replace masks but instead provide an additional protective layer.

Scott Pharma – 25.03.2025
SMI – 24/03/2025
Chemspec Europe – 27.02.2025
PHARMAP: Mon 14 October 2024, 10.36
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
L.B. Bohle – 08.04.2025